Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (NASDAQ: EBS) is a global life sciences company headquartered in the United States and focused on providing innovative preparedness and response solutions for public health threats. The company operates through three primary business segments: Commercial Products, Medical Countermeasures… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Emergent BioSolutions Inc. does
In the company’s own words
Emergent BioSolutions Inc. (NASDAQ: EBS) is a global life sciences company headquartered in the United States and focused on providing innovative preparedness and response solutions for public health threats. The company operates through three primary business segments: Commercial Products, Medical Countermeasures (MCM) Products, and Services.
The Commercial Products segment generates revenue from NARCAN® (naloxone HCl) Nasal Spray and KLOXXADO® (naloxone HCl) Nasal Spray, which are used for emergency treatment of opioid overdose. NARCAN® is available both as a prescription product and over-the-counter in the United States and Canada, sold through retail pharmacies, government agencies, law enforcement, and community organizations. KLOXXADO® is a prescription product acquired from Hikma Pharmaceuticals in 2025.
The MCM Products segment addresses chemical, biological, radiological, nuclear and explosive threats, as well as emerging infectious diseases. This portfolio includes ACAM2000® (smallpox and mpox vaccine), CYFENDUS® (anthrax vaccine adjuvanted), BioThrax® (anthrax vaccine), BAT® (botulism antitoxin), CNJ-016® (vaccinia immune globulin), ANTHRASIL® (anthrax immune globulin), Ebanga™ (monoclonal antibody for Ebola), TEMBEXA® (smallpox antiviral), and raxibacumab (anthrax monoclonal antibody). The United States government, particularly the Department of Health and Human Services, represents the primary customer for MCM products through procurement contracts and stockpiling arrangements.
The Services segment, which no longer meets quantitative thresholds as a reportable segment, provides contract development and manufacturing organization (CDMO) services including drug substance manufacturing, drug product formulation and filling, packaging, and development services across multiple technology platforms. The company maintains development and manufacturing facilities in the United States and Canada.
Emergent BioSolutions has undergone significant restructuring, including the 2023 divestiture of its travel health business to Bavarian Nordic and the 2025 sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. The company's website is www.emergentbiosolutions.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- GAITHERSBURG, MD
- Fiscal year end
- December
- CIK
- 1367644
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Emergent BioSolutions Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Emergent BioSolutions Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Emergent BioSolutions Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Emergent BioSolutions Inc.’s debt, $120.08M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.88%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Emergent BioSolutions Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Emergent BioSolutions Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Emergent BioSolutions Inc.'s last four quarterly filings that the numbers alone won't show?”